Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function

Department of Neurobiology and Anatomy, Program in Cancer Cell Biology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, 26506-9300.
Journal of Cancer Science and Therapy 11/2009; 1(2):52-61. DOI: 10.4172/1948-5956.1000009
Source: PubMed


Elevated Src kinase activity is linked to the progression of solid tumors, including head and neck squamous cell carcinoma (HNSCC). Src regulates HNSCC proliferation and tumor invasion, with the Src-targeted small molecule inhibitor saracatinib displaying potent anti-invasive effects in preclinical studies. However, the pro-invasive cellular mechanism(s) perturbed by saracatinib are unclear. The anti-proliferative and anti-invasive effects of saracatinib on HNSCC cell lines were therefore investigated in pre-clinical cell and mouse model systems. Saracatinib treatment inhibited growth, cell cycle progression and transwell Matrigel invasion in HNSCC cell lines. Dose-dependent decreases in Src activation and phosphorylation of the invasion-associated substrates focal adhesion kinase, p130 CAS and cortactin were also observed. While saracatinib did not significantly impact HNSCC tumor growth in a mouse orthotopic model of tongue squamous cell carcinoma, impaired perineural invasion and cervical lymph node metastasis was observed. Accordingly, saracatinib treatment displayed a dose-dependent inhibitory effect on invadopodia formation, extracellular matrix degradation and matrix metalloprotease 9 activation. These results suggest that inhibition of Src kinase by saracatinib impairs the pro-invasive activity of HNSCC by inhibiting Src substrate phosphorylation important for invadopodia formation and associated matrix metalloprotease activity.

Download full-text


Available from: Laura c Kelley
  • Source
    • "Together, these two studies provide clues that the ability of flavonoids to inhibit MMP secretion might be owing to the inhibition of invadopodia formation. Ammer et al. showed that inhibition of Src kinase results in inhibition of MMP-9′s secretion, causing an accumulation of MMP-9 in HNSCC cell lines [48]. Moreover, MMPs have to be recruited to the invadopodia in order to accomplish the degradation of the matrix. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Metastasis is a major cause of mortality in cancer patients. Invadopodia are considered to be crucial structures that allow cancer cells to penetrate across the extracellular matrix (ECM) by using matrix metalloproteinases (MMPs). Previously, we isolated a highly invasive A431-III subline from parental A431 cells by Boyden chamber assay. The A431-III cells possess higher invasive and migratory abilities, elevated levels of MMP-9 and an enhanced epithelial-mesenchymal transition (EMT) phenotype. In this study, we discovered that A431-III cells had an increased potential to form invadopodia and an improved capacity to degrade ECM compared with the original A431 cells. We also observed enhanced phosphorylation levels of cortactin and Src in A431-III cells; these phosphorylated proteins have been reported to be the main regulators of invadopodia formation. Flavonoids, almost ubiquitously distributed in food plants and plant food products, have been documented to exhibit anti-tumor properties. Therefore, it was of much interest to explore the effects of flavonoid antioxidants on the metastatic activity of A431-III cells. Exposure of A431-III cells to two potent dietary flavonoids, namely luteolin (Lu) and quercetin (Qu), caused inhibition of invadopodia formation and decrement in ECM degradation. We conclude that Lu and Qu attenuate the phosphorylation of cortactin and Src in A431-III cells. As a consequence, there ensues a disruption of invadopodia generation and the suppression of MMP secretion. These changes, in concert, bring about a reduction in metastasis.
    Full-text · Article · Aug 2013 · PLoS ONE
  • Source
    • "Several molecular target drugs that are already used in clinics or tested in preclinical or clinical trials may be used for targeting invadopodia formation. The small molecule Src/Abl inhibitors, saracatinib and dasatinib, block invadopodia-mediated invasion of head and neck cancer cells and breast cancer cells, respectively (Ammer et al., 2009; Pichot et al., 2009). We also reported that Iressa, a small molecule EGF-receptor inhibitor, blocks EGF-dependent invadopodia formation in breast cancer cells (Yamaguchi et al., 2005a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Invadopodia are actin-rich membrane protrusions formed by invasive cancer cells. Invadopodia mediate the focal degradation of pericellular extracellular matrix (ECM) by the localized proteolytic activity of matrix metalloproteinases (MMPs). Over the last 2 decades, much progress has been made in identifying the molecular components of invadopodia and understanding the molecular mechanisms underlying their formation. Although the physiological and pathological roles of invadopodia have long been elusive, emerging evidence has begun to reveal their importance in local invasion during cancer metastasis. This review highlights recent findings on the roles of invadopodia in cancer invasion and metastasis and discusses the possibility of and strategies for targeting invadopodia formation for the development of novel anticancer therapeutics.
    Full-text · Article · Jun 2012 · European journal of cell biology
  • Source
    • "In HNSCC and several other tumor types, cortactin is present in the cytoplasm and is enriched at cell-cell junctions [48], [60], [61]. The localization of pS418 cortactin at regions of HNSCC cellular contact within tumors resembles the localization pattern of pY421 cortactin in this tumor type [62]. The staining pattern of cortactin and its tyrosine phosphorylated form is reminiscent of that found in two-dimensional epithelial monolayers, where cortactin has been shown to be essential for Arp2/3-mediated actin remodeling resultant from E-cadherin homoligation and subsequent Src activity [63], [64]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor cell motility and invasion is governed by dynamic regulation of the cortical actin cytoskeleton. The actin-binding protein cortactin is commonly upregulated in multiple cancer types and is associated with increased cell migration. Cortactin regulates actin nucleation through the actin related protein (Arp)2/3 complex and stabilizes the cortical actin cytoskeleton. Cortactin is regulated by multiple phosphorylation events, including phosphorylation of S405 and S418 by extracellular regulated kinases (ERK)1/2. ERK1/2 phosphorylation of cortactin has emerged as an important positive regulatory modification, enabling cortactin to bind and activate the Arp2/3 regulator neuronal Wiskott-Aldrich syndrome protein (N-WASp), promoting actin polymerization and enhancing tumor cell movement.
    Full-text · Article · Nov 2010 · PLoS ONE
Show more